Pratteln / London (IT BOLTWISE) – Santhera Pharmaceuticals has concluded an exclusive agreement with Ikris Pharma Network to sell Agamree® (Vamorolon) in India. This partnership aims to improve access to innovative treatments for Duchenne Muskeldystrophy (DMD) and to expand the availability of AGAMREE® for patients from the age of four.
Today’s daily deals on Amazon! ˗ˋˏ$ˎˊ˗
Santhera Pharmaceuticals, a leading Swiss company in the field of neuromuscular diseases, has announced an important partnership with Ikris Pharma Network in India. This cooperation aims to introduce the innovative drug agamree® (Vamorolon) to treat Duchenne Muskeldystrophy (DMD) in India. The agreement has a term of five years and stipulates that Santhera receives a percentage of net sales.
Agamree® is a new drug that is characterized by its unique mechanism of action. It binds to the same receptor as glucocorticoids, but modifies its activity, which leads to a reduction in the typical side effects of steroids. These properties make Agamree a promising alternative to the current standard corticosteroids that are used at DMD.
The partnership with Ikris Pharma Network is a strategic step by Santhera to expand global access to Agamree. Ikris is known for its expertise in the field of rare diseases and will offer the drug via its established sales network in India. This is particularly important because DMD is a rare genetic disease that leads to progressive muscle weakness and for which there has been no healing so far.
Agamree in India is introduced as part of “Named-Patient-Sales”, a model that makes it possible to provide medication on an individual basis. This method ensures that patients who urgently rely on innovative treatments are given access to them. The cooperation between Santhera and Ikris underlines the commitment of both companies to improve the quality of life of DMD patients and to facilitate access to life-changing therapies.
*Order Amazon credit card without an annual fee with 2,000 euros! a‿z
Bestseller no. 1 ᵃ⤻ᶻ “Ki Gadgets”
Bestseller no. 2 ᵃ⤻ᶻ “Ki gadgets”
Bestseller no. 3 ᵃ⤻ᶻ “Ki gadgets”
Bestseller no. 4 ᵃ⤻ᶻ “Ki gadgets”
Bestseller no. 5 ᵃ⤻ᶻ “Ki Gadgets”
Additions and information to the editorial team by email to DE-Info[at]it-boltwise.de. Since we cannot rule out rarely occurring AI Hallucinations in the event of AI generated news and content, we ask you to contact and inform us for false information and misinformation via email. Please do not forget to name the article headline in the email: “Santhera and Ikris Pharma: New partnership for the treatment of DMD in India”.
